Laxai Pharma Acquires OSR Solutions
Laxai Pharma has completed the asset purchase of OSR by investing $3.6m financed through the issuance and sale of debt and equity securities. The company now has 60.1m
The European Commission (EC) has granted orphan designation to Lundbeck’s investigational monoclonal antibody asedebart (Lu AG13909) for the treatment of Cushing’s syndrome of endogenous origin.
Progen Pharmaceuticals said that the new contract further validates PharmaSynth as an important Australian based contract manufacturer with expertise in recombinant proteins, bacterial and viral vaccines, whole cell